Yes, the title of this article is misleading, dangerous crap. Sorry, but I just took it directly from the ad — the ad I’m writing about today is from Patrick Cox for his Breakthrough Technology Alert, a relatively expensive ($895) newsletter that focuses on, well, breakthrough technologies, mostly stocks that we’d classify as biotechs or leading edge tech stocks, and almost all very small companies. I had a short list of several interesting teasers to focus on for you this morning, and the fact that this is being pitched as “The Last Stock You’ll Ever Need” pushed me over the edge.
So which is this last stock that you’ll ever need to buy? The ad is a very similar pitch to what Patric Cox has used before — his ads almost always talk about being in on the ground floor of universe-shaking ideas, of building generational wealth through incredible breakthroughs. Nothing boring in here about solid balance sheets, dividends, diversification, or even patience — though of course, most of the stocks he writes about are far from becoming large and profitable enterprises.
This is the most tempting kind of stock pitch: that there’s an idea so good that it can change the way you live, so good, indeed, that it can change the way your grandchildren live as you build a generation-spanning cache of lucre. The most prominent pitches from him in recent years have been for stem cell stocks like Geron (GERN) and BioTime (BTX) or early-stage biotech stocks fighting cancer or alzheimer’s, and occasionally for cutting edge stocks in other areas, like Lightbridge (LTBR) for their thorium reactor technology or NVE Corp (NVEC) for their spintronics patents. The same stocks tend to repeat themselves from time to time in his pitches, so a few of those (and maybe also today’s, we’ll find out soon) were also pitched in his ad a couple months back that promised a revolution whose impact would rival that of the printing press.
Today? We’re told, of course, that it might be the last stock you’ll ever want to buy — so who is it?
I’m not going to do a lot of direct quoting, since Cox doesn’t make the transcript of his “video” presentation available, but I’ll give you the gist. Here, at least, is the bold type intro:
“Only a Handful of Researchers and Experts In the Entire World Know What You’re About to See…
“The LAST STOCK You’ll Ever Need
“You’re about to witness a shocking, hidden story.
“This could also be the biggest market story in history.
“You must act on this urgent wealth creation event before Midnight, Monday, May 30th.”
The urgency of May 30 is not that there’s necessarily going to be any news out of this company … it’s that they’ll be taking down the ad presentation. Which will be a horrific loss to all of us, I’m sure.
But Cox does indicate that there are good things ahead in the near future for this company — partly because of his sunny interpretation of their actual work, and partly because of insider buying, which provides our first clue.
He says that the CEO recently bought 500,000 shares with his own money and now owns about 9% of the shares, and that insiders overall own about 30% … which does sound promising.
And he names an impressive list of institutional investors who also own the shares, like Goldman Capital, BlackRock, and Vanguard … though of course all good little Gumshoes know that finding a decent-sized stock without an impressive list of institutional investors is almost impossible. So that’s another hint, though not a particularly exciting factoid.
We get more hints as well — including that researchers at a “famous institute in Florida” and at Johns Hopkins University are “absolutely floored” by the breakthrough potential of this company … potential that Cox applies most urgently to Alzheimer’s Disease but that he says could also be a “supertreatment” for a baker’s dozen of big diseases and nasty conditions, including cancer, macular degeneration, stroke, obesity, erectile dysfunction, allergies, Crohn’s Disease, rheumatoid arthritis … well, you name it.